US Patent

US12042487 — Method for reducing side effects from administration of phosphodiesterase-4 inhibitors

Formulation · Assigned to Arcutis Biotherapeutics Inc · Expires 2037-06-07 · 11y remaining

Vulnerability score 55/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a method for reducing gastrointestinal side effects of a PDE-4 inhibitor, such as roflumilast, by topically administering it with phosphate ester surfactants.

USPTO Abstract

A method for altering the PK profile of a pharmaceutical formulation containing a PDE-4 inhibitor, such as roflumilast, to reduce the spike in Cmax. The spike in Cmax is reduced by topically administering the PDE-4 inhibitor in combination with one or more phosphate ester surfactants. Reducing the spike in Cmax will reduce gastrointestinal side effects and result in better patient compliance.

Drugs covered by this patent

Patent Metadata

Patent number
US12042487
Jurisdiction
US
Classification
Formulation
Expires
2037-06-07
Drug substance claim
No
Drug product claim
Yes
Assignee
Arcutis Biotherapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.